$7 Mln
$-21 Mln
--
As on 22-Sep-2023 15:59 EDT
$0.00
•
0.25%
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
ReShape Lifesciences (RSLS)
| -90.91 | -48.93 | -69.81 | -96.34 | -83.31 | -82.68 | -55.26 |
|
S&P BSE Sensex*
| 8.52 | 1.18 | 4.83 | 13.64 | 21.78 | 12.71 | 12.73 |
|
#
| -- | -- | -- | -- | -- | -- | -- |
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|
|---|---|---|---|---|---|---|---|
|
ReShape Lifesciences (RSLS)
| -91.78 | -53.80 | -38.26 | 125.49 | -82.60 | -26.00 | 1,437.28 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
The total asset value of ReShape Lifesciences Inc. (RSLS) stood at $ 13 Mln as on 31-Mar-23
The share price of ReShape Lifesciences Inc. (RSLS) is $0.612800 (NASDAQ) as of 22-Sep-2023 15:59 EDT. ReShape Lifesciences Inc. (RSLS) has given a return of -83.31% in the last 3 years.
ReShape Lifesciences Inc. (RSLS) has a market capitalisation of $ 7 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.
The P/B ratio of ReShape Lifesciences Inc. (RSLS) is 0.16 times as on 02-Jun-2023, a -0.96% premium to its peers’ median range of 4.02 times.
Since, TTM earnings of ReShape Lifesciences Inc. (RSLS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the ReShape Lifesciences Inc. (RSLS) and enter the required number of quantities and click on buy to purchase the shares of ReShape Lifesciences Inc. (RSLS).
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
The CEO & director of Mr. Dan W. Gladney. is ReShape Lifesciences Inc. (RSLS), and CFO & Sr. VP is Mr. Thomas Stankovich.
The promoters of ReShape Lifesciences Inc. (RSLS) have pledged 0% of the total equity as on Mar-23.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
3
|
|
|
3
|
|
|
1
|
|
|
1
|
| ReShape Lifesciences Inc. (RSLS) | Ratios |
|---|---|
|
Return on equity(%)
|
-443.92
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
0
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of ReShape Lifesciences Inc. (RSLS) was $-21 Mln.
$7.41 Mln
$11.91 Mln
$-21.39 Mln
$3.86 Mln
$0.17 Mln
High
$0.57 - 22.40
2,942,310
NASDAQ: RSLS
San Clemente, CA
https://www.reshapelifesciences.com
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band... System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
